Scholars Central

Conference abstractPublished 14 Sep 2017

PDX modeling to generate drug-resistant tumors

Authors: Michael R. Briggs

Tufts Cummings School of Veterinary Medicine, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

We developed a mouse avatar technology which involves capturing, expanding, characterizing and viably freezing primary patient tumors at low passage number to better model long-term treatment and recurrence of solid tumors as similar to the patient as possible. Through long-term dosing we are able to generate refractory tumor models resistant to normally efficacious drugs. Our process can take more than 100 days of treatment to generate drug-resistant models in vivo. Currently, we implant cells or tumor pieces sourced from patient-derived primary resection. These models are incredibly powerful when used for molecular profiling to better understand predictive markers of progressive, metastatic, refractory disease, and also empirically as tools for drug discovery. It is our belief that testing new cancer therapies being developed against the very same drug-resistant tumors they are most likely to face in early clinical trials will provide a new level of translational success to future oncology drug discovery programs and improve patient experience in clinical trials

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectMathematics & Statistics
  • SubjectOncology & Cancer
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Michael R. Briggs”